Breaking AI & Tech News Analyzed

A recent experiment with an autonomous AI agent, named Gaskell, has provided a glimpse into the capabilities and limitations of these emerging technologies. Gaskell, created by a team of individuals, was tasked with organizing a party in Manchester, which the author attended.Gaskell's autonomous nature was put to the test as it interacted with potential sponsors and event staff, showcasing both impressive abilities and significant limitations. The AI agent was able to secure a venue, arrange for catering, and even attempt to negotiate with vendors, although it ultimately failed to deliver on some promises, such as ordering pizza.The event itself was surprisingly ordinary, with around 50 attendees engaging in discussions about AI over beers and snacks. Despite some initial missteps, including a failed attempt to secure a venue at the Manchester Art Gallery, Gaskell's human employees were able to step in and ensure the event's success.Gaskell's limitations were evident in its inability to use a phone or credit card, highlighting the current constraints of autonomous AI agents. However, the experiment also demonstrated the potential for these technologies to autonomously manage complex tasks and interact with humans in meaningful ways.The author notes that Gaskell's capabilities, although imperfect, represent a significant step forward in AI development, and that similar experiments are likely to become more common in the future.

On a sun‑lit picnic beside Canberra’s Molonglo River, a tartan blanket, a bottle of wine, crusty baguette, cheese and a daring chicken‑and‑grape salad from a gourmet magazine marked the beginning of a romance that would be defined by food.Their shared appetite for culinary experimentation quickly turned into a series of kitchen showdowns—debates over meat doneness, oven temperatures, seasoning ratios and the eternal butter‑vs‑oil dilemma. While the clashes were frequent, the meals they produced together often became celebrated triumphs.Over the years, their lives were chronicled in the spines of recipe books and the aromas of countless dinners. From the quest for the perfect loaf to the fiery sting of chilies that left a lasting impression, each dish mapped the highs and lows of their partnership.He gravitated toward savoury mains; she honed a talent for desserts. Their culinary quirks—her habit of returning leftovers to the fridge, his ritual of swaddling roasted meat in tea towels—added both friction and flavor to their shared table.Even after their separation, the couple’s kitchen remains a shared space. A well‑worn ceramic baking tray, scarred by years of roasting turkeys, chickens and lamb, still serves as the foundation for gravy‑making and other culinary rituals during holiday gatherings.One of his most enduring contributions is a dish they call Pasta Dimanche. Born from a pantry raid on a Sunday night, the pasta blends diced capsicum, carrot, purple onion, garlic, celery, parsley and tomato with a tin of tuna, cracked pepper, salt and a splash of Tabasco and green chilli sauce. The result is a vibrant, summery plate that celebrates colour, texture and the surprise harmony of warm and crisp.Recipe: Pasta Dimanche (Serves 4)Ingredients:1 red onion, finely chopped1 carrot, finely diced3 garlic cloves, finely chopped1 yellow capsicum, finely chopped1 green capsicum, finely chopped1 red capsicum, finely chopped1 cup finely chopped parsley370 g tin tuna, drained1 tsp Tabasco1 tsp green TabascoDried pasta of choice (to serve)Method:1. Toss the vegetables, garlic, parsley and tuna in a large bowl; season with Tabasco, salt and pepper.2. Cook pasta in salted boiling water until al dente; drain.3. Divide pasta among four bowls, top with the tuna‑vegetable mix, and serve.Despite their split, they continue to exchange food news, recipe links from the New York Times, and tips on premium ingredients—proving that a shared love of cooking can outlast even the most intimate of relationships.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

As the 2026 local and regional elections draw nearer, the spectre of Trussonomics looms large over the British political landscape. From the Conservatives to the Greens, parties are unveiling extravagant fiscal promises that they claim can be funded by cuts elsewhere or additional borrowing, while insisting the broader economy will remain unharmed. Critics warn that any adverse effects will inevitably be shifted onto people and businesses outside the parties' core constituencies, effectively socialising the risk. Only Keir Starmer and his Labour cabinet appear to resist the pressure to re‑engineer the economy without acknowledging inevitable spill‑overs or extra costs. Former Prime Minister Liz Truss famously pledged £45 bn of tax cuts, financed through extra borrowing and so‑called welfare “efficiencies”. The plan was pitched as a catalyst for an entrepreneurial surge that would lift the UK out of a prolonged period of low productivity. Heading into May’s local polls, the Conservatives are touting a new “big‑spending” agenda after recent welfare cuts, highlighted by a headline pledge to shrink the welfare bill by £23 bn. Shadow Chancellor Mel Stride declared that the “culture of ‘something for nothing’ must end, now”. Green Party leader Zack Polanski has softened some of his party’s more radical proposals, yet the manifesto remains vague. Earlier drafts featured a litany of “free lunches”, signalling an ambition to raise taxes by **more than £170 bn a year** by the end of the next parliament. Key components of the Green plan include a £90 bn annual carbon tax and a matching increase in day‑to‑day public spending, alongside a proposed £90 bn boost to the capital‑spending budget (raising it from £160 bn to £250 bn per year). Reform UK has embraced Trussonomics with gusto, promising to raise the income‑tax threshold from £12,570 to £20,000 – a move that would cost the exchequer **over £40 bn each year**. Underlying many of these pledges is a belief that the UK can reverse a century of economic decline with a “magician’s wand”, ignoring potential repercussions for financial markets, trading partners, and a rapidly disintegrating global order. While the article briefly references the United States and France, the French electorate’s recent rejection of similarly flamboyant policies in local elections serves as a cautionary tale: voters in key cities like Paris and Marseille opted for centrist candidates over the radical platforms of Marine Le Pen’s National Rally and Jean‑Luc Mélenchon’s LFI. The broader context is a decade marked by two major wars, a quantum technological shift, and accelerating climate change – none of which offer quick‑fix solutions. Labour’s economic strategy, championed by Rachel Reeves, hinges on an early‑parliament spending surge intended to generate growth before the next general election. However, the damage inflicted by the previous government is still being reassessed, with the public‑finance gap now appearing larger than the £22 bn initially highlighted by Reeves. Labour still holds considerable funds earmarked for investment, but bureaucratic inertia in Whitehall hampers swift action, and Starmer bears responsibility for this paralysis. Demonstrating tangible returns on public spending – with HS2 currently the sole benchmark – could justify future tax increases on higher earners, provided the money is not wasted. In an uncertain world, the article argues that rational, evidence‑based governance is preferable to “outlandish initiatives” that create a multitude of losers. Ultimately, the piece concludes that Truss’s experiment was a disaster not merely because of the misguided belief that tax cuts can drive sustainable growth in a mature economy, but because it relied on an imagined “escape hatch” to propel the UK to a higher economic plane.

Mary Beth Hurt died on 28 March 2026 at the age of 79, closing a four‑decade career that blended intellectual cinema with acclaimed stage work. Born in Marshalltown, Iowa, she entered the film world with Woody Allen’s experimental drama Interiors (1978), earning a BAFTA nomination for Best Newcomer alongside Christopher Reeve.Although Interiors was a modest critical success, it proved financially profitable, grossing $10 million on a $3 million budget. Hurt’s portrayal of the directionless Joey marked the start of a career defined by thoughtful, understated performances.Her next high‑profile role came as Helen Holm, the college‑professor wife of Robin Williams’s titular character in The World According to Garp (1982). The film’s daring tonal shifts – including a shocking car‑crash scene – earned Oscar nominations for John Lithgow and Glenn Close, while giving Hurt a rare chance to play a fully sexual woman.Early setbacks included losing the lead in Joan Micklin Silver’s Head Over Heels (1979) to Jamie Lee Curtis and a troubled turn in the melodrama A Change of Seasons (1980), which suffered from production turmoil and poor box‑office returns.On stage, Hurt distinguished herself with three Tony nominations: for Pinero’s Trelawny of the ‘Wells’ (1976) opposite a debuting Meryl Streep, for a 1982 revival of Beth Henley’s Crimes of the Heart, and for Michael Frayn’s Benefactors (1986). She debuted on Broadway in 1974’s revival of William Congreve’s Love For Love opposite Glenn Close.Her personal life intersected with her professional world. She married fellow actor William Hurt in 1971, divorcing in December 1982, and later wed director Paul Schrader in August 1983. Collaborations with Schrader included Light Sleeper (1992), Affliction (1997) and The Walker (2007).Later film work featured a supporting turn in Karen Moncrieff’s feminist thriller The Dead Girl (2006), which earned her an Independent Spirit Award nomination, and a cameo in Martin Scorsese’s The Age of Innocence (1993). Her final screen appearance was in the small‑town drama Change in the Air (2018), filmed before a diagnosis of Alzheimer’s disease.Reflecting on her craft, Hurt once said, "I never felt very beautiful or incredibly smart or witty, so I was always looking for something about the role that intrigued me… more fascinating than the gold‑medal moments."She is survived by husband Paul Schrader and their two children, Molly and Sam.

The Royal Shakespeare Company's upcoming production of Bertolt Brecht's 'The Resistible Rise of Arturo Ui' offers a timely warning against the rise of fascism, echoing current events in Britain and the US. The play, a satire about the rise of Hitler, features Mark Gatiss as Arturo Ui and music by the alternative rock band Placebo.Gatiss notes that the rhetoric used by Arturo Ui is 'the same rhetoric today', describing it as 'really frightening'. The play's themes of corruption, violence, and the dangers of unchecked power are as relevant today as they were when Brecht wrote the play in 1941.The production features a unique blend of music and theatre, with Placebo's Brian Molko and Stefan Olsdal creating a score that captures the brutality and urgency of the play. The music is designed to be 'loud and abrasive', with Molko describing the process of creating the score as 'like being in a dark room and feeling your way around'.Gatiss, who has a history of playing villains, says that he has put a moratorium on playing characters akin to Sherlock's Mycroft Holmes, but was drawn to the role of Arturo Ui after seeing a production at Darlington Civic Theatre with Robin Askwith in the lead. The play's director, Seán Linnen, encouraged the cast to experiment and find new ways to bring the play to life.The production's themes and message are particularly relevant in today's world, with Gatiss stating that 'we feel helpless' in the face of rising fascism. The play's epilogue, which calls on the audience to act against the rise of fascism, still gives Gatiss 'goosebumps'. As Gatiss notes, 'you have to do something. Go down swinging, at least.'

A federal judge has dismissed 10 out of 13 claims made by Blake Lively against director Justin Baldoni, including allegations of sexual harassment, conspiracy, and defamation. The lawsuit, which centers around the filming of 'It Ends With Us,' a domestic abuse drama where Lively and Baldoni starred as characters with intimate scenes, will proceed to trial next month on claims of a retaliatory campaign against Lively.Baldoni's lawyer, Bryan Freedman, described the defendants as 'very good people who have not engaged in this sexual harassment as alleged.' He expressed satisfaction with the court's ruling, stating it confirms what his legal team believed from the start.The judge's 152-page opinion emphasized that Lively's claims must be viewed in the context of the film's production, noting that creative artists need space to experiment within scripted scenes without fear of liability for sexual harassment. The court also determined Lively was working as an independent contractor, not an employee, which impacted her ability to bring sexual harassment claims.Lively's attorney, Mike Gottlieb, responded that the ruling was based on 'legal technicalities' and not an endorsement of the defendants' conduct. A trial is scheduled for May 18.

The BBC Philharmonic, under the baton of John Storgårds, has released an album featuring Dmitri Shostakovich's Symphonies No 2 and 5. This pairing brings together one of the composer's most familiar works with one of his lesser-known pieces.The Symphony No 2, commissioned as propaganda for the 10th anniversary of the October Revolution, is an early experiment by the 21-year-old Shostakovich. It begins with eerie, foggy strings that slide up and down in an intangible, almost pitchless way, more akin to a sound effect than music. As it builds, the symphony becomes a perpetual motion melee, culminating in a celebratory chorus singing 'October, the Commune and Lenin'.In contrast, the Symphony No 5, written a decade later, showcases a more mature composer. Storgårds' interpretation doesn't quite capture the depth of darkness in the first movement, but his warmth in the harmonies brings the music to life. The third movement has a compelling stillness, while the finale expertly increases tension through small tempo changes.This album review highlights the stark contrast between Shostakovich's early experimentation and his later mastery. The performance by the BBC Philharmonic and John Storgårds is effective, making this album a valuable addition to any classical music collection.